Delivering the precision oncology paradigm: reduced R&D costs and greater return on investment through a companion diagnostic informed precision oncology medicines approach

Abstract

Background Precision oncology medicines represent a paradigm shift compared to non-precision oncology medicines in cancer therapy, in some situations delivering more clinical benefit, and potentially lowering healthcare costs. We determined whether employing a companion diagnostic (CDx) approach during oncology medicines development delivers effective therapies that are within the cost constraints of current health systems. R&D costs of developing a medicine are subject to debate, with average estimates ranging from $765 million (m) to $4.6 billion (b). Our aim was to determine whether precision oncology medicines are cheaper to bring from R&D to market; a secondary goal was to determine whether precision oncology medicines have a greater return on investment (ROI). Method Data on oncology medicines approved between 1997 and 2020 by the US Food and Drug Administration (FDA) were analysed from the Securities and Exchange Commission (SEC) filings. Data were compiled from 10-K, 10-Q, and 20-F financial performance filings on medicines’ development costs through their R&D lifetime. Clinical trial data were split into clinical trial phases 1–3 and probability of success (POS) of trials was calculated, along with preclinical costs. Cost-of-capital (CoC) approach was applied and, if appropriate, a tax rebate was subtracted from the total. Results Data on 42 precision and 29 non-precision oncology medicines from 56 companies listed by the National Cancer Institute which had complete data available were analysed. Estimated mean cost to deliver a new oncology medicine was $4.4b (95% CI, $3.6–5.2b). Costs to bring a precision oncology medicine to market were $1.1b less ($3.5b; 95% CI, $2.7–4.5b) compared to non-precision oncology medicines ($4.6b; 95% CI, $3.5–6.1b). The key driver of costs was POS of clinical trials, accounting for a difference of $591.3 m. Additional data analysis illustrated that there was a 27% increase in return on investment (ROI) of precision oncology medicines over non-precision oncology medicines. Conclusion Our results provide an accurate estimate of the R&D spend required to bring an oncology medicine to market. Deployment of a CDx at the earliest stage substantially lowers the cost associated with oncology medicines development, potentially making them available to more patients, while staying within the cost constraints of cancer health systems.

Cancer medicines: a private vice for public benefit?

“…It’s worth noting that in this analysis none of the newer immuno-oncology drugs were included because it it is too early to assess the costs of their R&D and ROI. However, the analysis included the most recent tranche of targeted cancer medicines drawing on detailed financial data filed with the US Securities and Exchange Commission (SEC) [ 3 ].…”

Academia and society should join forces to make anti‐cancer treatments more affordable

“…Close collaboration with other centers and hospitals (see Fig. 1 ) is needed to guarantee swift recruitment of patients and ensure that associated diagnostic tests [ 6 ] and patient monitoring meet the standards required for robust, data‐rich clinical trials that also can provide insight into benefit/cost relationship [ 7 ]. Such CCCs and networks thereof are not only well‐positioned to develop new treatments.…”

The Buzz Surrounding Precision Medicine: The Imperative of Incorporating It into Evidence-Based Medical Practice

“…Henderson, R.H. et al's [45] study underlined the potential cost-saving benefits of incorporating companion diagnostics (CDx) in early oncology medicine development. By integrating CDx, there could be a significant reduction in developmental costs, offering a pathway to enhance accessibility within constrained cancer health systems.…”